Seres Therapeutics (NASDAQ:MCRB) Lowered to "Sell" Rating by StockNews.com

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) was downgraded by StockNews.com from a "hold" rating to a "sell" rating in a report issued on Thursday.

MCRB has been the topic of a number of other reports. Chardan Capital restated a "buy" rating and issued a $25.00 price target on shares of Seres Therapeutics in a report on Thursday, March 20th. The Goldman Sachs Group reduced their price target on Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating for the company in a research report on Friday, March 14th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $80.00.

Seres Therapeutics Price Performance

Shares of Seres Therapeutics stock traded down $0.68 on Thursday, hitting $8.55. The company had a trading volume of 83,099 shares, compared to its average volume of 154,440. The stock has a 50-day moving average of $12.10 and a 200-day moving average of $14.83. Seres Therapeutics has a twelve month low of $7.18 and a twelve month high of $30.60. The firm has a market capitalization of $74.54 million, a P/E ratio of -37.17 and a beta of 2.89.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Millennium Management LLC raised its position in shares of Seres Therapeutics by 77.2% in the fourth quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company's stock valued at $1,505,000 after purchasing an additional 788,762 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Seres Therapeutics by 8.8% during the fourth quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company's stock worth $1,256,000 after acquiring an additional 121,793 shares during the period. Vontobel Holding Ltd. grew its position in shares of Seres Therapeutics by 15.7% in the first quarter. Vontobel Holding Ltd. now owns 1,085,966 shares of the biotechnology company's stock valued at $760,000 after purchasing an additional 147,671 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Seres Therapeutics by 15.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company's stock worth $720,000 after purchasing an additional 117,107 shares during the period. Finally, State Street Corp lifted its holdings in Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock worth $363,000 after purchasing an additional 43,700 shares during the last quarter. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.